Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors.
- Resource Type
- Academic Journal
- Authors
- Tu CY; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.; Hsia TC; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.; Health Science and Industry, College of Health Care, China Medical University, Taichung, Taiwan.; Lin YC; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.; Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan.; Liang JA; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.; Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan.; Li CC; Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan.; Chien CR; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.; Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan.
- Source
- Publisher: Hindawi Publishing Corporation Country of Publication: Egypt NLM ID: 9433332 Publication Model: eCollection Cited Medium: Internet ISSN: 1916-7245 (Electronic) Linking ISSN: 11982241 NLM ISO Abbreviation: Can Respir J Subsets: MEDLINE
- Subject
- Language
- English
Background: The effectiveness of definitive radiotherapy (RT) for patients with clinical stage IIIB or IIIC lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutations who received first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) is unclear.
Methods: Taiwan Cancer Registry data were used in this retrospective cohort study to identify adult patients diagnosed with EGFR-mutated stage IIIB or IIIC lung adenocarcinoma between 2011 and 2020. Patients treated with first- or second-generation EGFR TKIs were classified into RT and non-RT groups. Propensity score (PS) weighting was applied to balance covariates between groups. The primary outcome was overall survival (OS), and the incidence of lung cancer mortality (ILCM) was considered as a supplementary outcome. Additional supplementary analyses were conducted to assess the robustness of the findings.
Results: Among 270 eligible patients, 41 received RT and 229 did not. After a median follow-up of 46 months, PS-weighted analysis showed the PS-weighted hazard ratio of death for the RT group compared to the non-RT group was 0.94 (95% CI: 0.61-1.45, p = 0.78). ILCM rates did not differ significantly between the two groups. Supplementary analyses yielded consistent results.
Conclusion: The addition of definitive RT to first- or second-generation EGFR TKI treatment does not significantly improve OS of patients with EGFR-mutated stage IIIB or IIIC lung adenocarcinoma. NCT03521154NCT05167851.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2024 Chih-Yen Tu et al.)